JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma

Inclusion Criteria: Patients must meet all of the following inclusion criteria to be enrolled： * Age range: 18 to 80 years old (inclusive), both male and female are acceptable； * ECOG: 0-2； * B-cell non-Hodgkin's lymphoma expressing CD20 antigen that has been pathologically diagnosed； * At least one measurable lesion meeting the criteria specified in the Lugano 2014 response assessment； Acceptable organ function at screening； Exclusion Criteria: * A history of severe allergy to monoclonal antibody therapy (or recombinant antibody-related fusion protein)； * Previously received CD20-CD3 bispecific antibody treatment； * Previous allogeneic hematopoietic stem cell transplantation； * Previous solid organ transplantation； * History of autoimmune diseases； * Patients with a history of macrophage activation syndrome (MAS)/ hemophagocytic lymphohistiocytosis (HLH)； * Patients with a history of progressive multifocal leukoencephalopathy (PML)； * A known or suspected history of CNS lymphoma (including primary or secondary)； * There is pleural effusion, peritoneal effusion or pericardial effusion that requires treatment (such as puncture or drainage)；